← Back to headlines
Syndax Pharmaceuticals Targets $400M Operating Expense by 2026 Amid Revuforj Expansion
Syndax Pharmaceuticals has outlined an operating expense target of approximately $400 million for 2026, driven by the expansion of its drug Revuforj in NPM1.
1 May, 02:52 — 1 May, 02:52
Sources
Showing 1 of 1 sources
